Molecular Formula | C18H22N2O |
Molar Mass | 282.38 |
Density | 1.0741 (rough estimate) |
Melting Point | 141-143℃ (ethanol ) |
Boling Point | 424.99°C (rough estimate) |
Storage Condition | -20℃ |
Refractive Index | 1.5700 (estimate) |
MDL | MFCD00209853 |
Physical and Chemical Properties | Bioactive Tyrphostin 9 (SF 6847, RG-50872) is the first EGFR inhibitor with IC50 of 460 μM, which is more effective on PDGFR and IC50 of 0.5 μM. |
Use | Uses the tyrosine phosphorylation inhibitor A9 (tyrphostin-9) can act as an effective uncoupling agent for oxidative phosphorylation and can inhibit differentiation of preadipocytes into mature adipocytes, thereby preventing adipocyte formation. Tyrphostin-9 is a very low toxic cytoprotectant (in vitro and in vivo) that inhibits TNF-induced human neutrophil respiratory burst, but does not inhibit its bactericidal activity, and can be used in the treatment of vascular intimal hyperplasia disease. In addition, because the tyrosine phosphorylation inhibitor A9 is structurally very similar to casein 9, it can strongly activate the cytoprotective gene by inducing the nuclear translocation of the transcription factor Nrf2, tyrphostin-9 is likely to exert a cytoprotective effect through this pathway. |
Hazard Symbols | T - Toxic |
Risk Codes | 23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. |
Safety Description | S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | UN 2811 6.1/PG 3 |
Raw Materials | 3,5-Di-tert-butyl-4-hydroxybenzaldehyde Malononitrile |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.541 ml | 17.707 ml | 35.413 ml |
5 mM | 0.708 ml | 3.541 ml | 7.083 ml |
10 mM | 0.354 ml | 1.771 ml | 3.541 ml |
5 mM | 0.071 ml | 0.354 ml | 0.708 ml |
melting point | 141-143℃ (ethanol ) |
boiling point | 424.99°C (rough estimate) |
density | 1.0741 (rough estimate) |
refractive index | 1.5700 (estimate) |
storage conditions | Inert atmosphere,Room Temperature |
solubility | ethanol: 20 mg/mL |
acidity coefficient (pKa) | 7.55±0.40(Predicted) |
morphology | solid |
color | yellow |
The anhydrous DMF solution (3mL) of 3, 5-di-tert-butyl-4-hydroxybenzaldehyde (244 mg,1.0 mmol) and malononitrile (80 mg,1.2 mmol) was refluxed for 10h. The solvent was removed by vacuum distillation, and the residue was purified by column chromatography on silica gel (hexane/Et2O,1:1) to obtain tyrosine phosphorylation inhibitor A9(233mg,83%) as yellow solid: mp 131-134 ℃. 1H NMR (CDCl3,400 MHz): d 7.81 (s, 2H), 7.65 (s, 1H), 6.06 (s, 1H), 1.47(s, 18H). EI-MS: m/z 282 (M ). Anal.calcd forC18H22N2O(Mr 282.4): C, 76.56; H, 7.85; N, 9.92.Found: C, 76.34; H, 7.66; N, 9.63. logP: 5.02 (calcd),2.32 (obsd). dGW: 62.4 KJ. pKa: 6.87 (ref36, 6.80)UV-vis max: 464 nm (10,031), 364 nm (11,101).
SF 6847 inhibits herpes simplex virus type 1 (HSV-1) replication with IC50 of 40 nM. SF 6847(50 nM) partially reverses sodium orthovanadate-induced HSV-1 plaque formation. SF 6847(<400 nm) reduces phosphorylation of viral phosphorylated protein in a dose-dependent manner, but SF 6847(<800 nm) induces a decrease in protein synthesis, which is not dose-dependent. SF 6847 acts on human fibroblasts and inhibits PDGF-induced tyrosine phosphorylation of LRP in membrane invagination fossa, indicating that PDGF-BB-mediated LRP activation requires tyrosine phosphorylation and thus activates PDGFR-β. SF 6847 (1 mM) acts on DNA synthesis in fetal lung cells and inhibits strain-induced stimulation. SF 6847((1 μM) increased exon 10 of the outer MAPT. SF 6847 does not affect the translation or stability of the two mRNAs. SF 6847(1.6 μM) acts on SHSY-5Y cells, increasing MAPT exon 10 by 2 times.
Target | Value |
PDGFR | 0.5 μM |
EGFR | 460 μM |